Scinai Immunotherapeutics (SCNI) Notes Payables (2021 - 2026)

Scinai Immunotherapeutics (SCNI) posted Notes Payables of -$12.5 million for Q4 2025, down 3370.42% sequentially from $382000.0 in Q4 2022.

Scinai Immunotherapeutics (SCNI) Notes Payables (2021 - 2026) Analysis & Trends

Scinai Immunotherapeutics has reported Notes Payables for 3 years, with the latest figure at -$12.5 million in Q4 2025.

Quarterly Notes Payables changed N/A year-over-year to -$12.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$12.5 million (changed N/A YoY) and the FY2025 annual result came in at -$12.5 million, changed N/A from the prior year.
Notes Payables fell to -$12.5 million in Q4 2025 per SCNI's latest filing, from $382000.0 in the prior quarter.
Over five years, Notes Payables peaked at $382000.0 in Q4 2022 and troughed at -$12.5 million in Q4 2025.
A 3-year average of -$3.9 million and a median of $375000.0 in 2021 frame the typical range for Notes Payables.
The widest YoY moves for Notes Payables: up 1.87% in 2022, down 1.87% in 2022.
Over 3 years, Notes Payables stood at $375000.0 in 2021, then gained by 1.87% to $382000.0 in 2022, then tumbled by 3370.42% to -$12.5 million in 2025.
According to Business Quant data, Notes Payables over the past three periods registered -$12.5 million, $382000.0, and $375000.0 for Q4 2025, Q4 2022, and Q4 2021 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	Scinai Immunotherapeutics	1.08 Mn	-3.11 Bn	-1.12 Mn

Download Data